PEAK6 Investments’s Sage Therapeutics SAGE Stock Holding History

PEAK6 Investments’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,500	Closed	-$315K	–	4609
2023 Q1	$315K	Sell	7,500 -77,200	-91%	-$3.32M	﹤0.01%	2763
2022 Q4	$3.23M	Sell	84,700 -14,400	-15%	-$550K	0.02%	974
2022 Q3	$3.88M	Buy	+99,100	New	+$3.83M	0.02%	1004

Other funds holding SAGE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

PEAK6 Investments's SAGE Position: Q4 2023 in Review

PEAK6 Investments sold out of Sage Therapeutics (SAGE) in Q4 2023, closing a stake of 15,000 shares — an estimated $309K sold.

PEAK6 Investments first reported a position in SAGE in Q3 2018 and held it in 11 quarters. The position peaked at $423K in Q2 2023. 201 funds tracked by Wall St. Rank hold SAGE as of Q4 2023.

PEAK6 Investments reported no remaining Sage Therapeutics position as of Q4 2023 after selling out during the quarter.
PEAK6 Investments sold 15,000 Sage Therapeutics shares in Q4 2023, an estimated $309K.
PEAK6 Investments first reported a position in Sage Therapeutics in Q3 2018 and held it in 11 quarters.
PEAK6 Investments's Sage Therapeutics position peaked at $423K in Q2 2023.
201 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2023.

Based on PEAK6 Investments's 13F filing for Q4 2023, filed 13 Feb 2024.